FDA approves label changes on DPD deficiency for fluorouracil injection products
The FDA has approved updated safety labeling addressing dihydropyrimidine dehydrogenase (DPD) deficiency for fluorouracil injection products.
The FDA has issued an approval covering safety labeling changes related to DPD deficiency for fluorouracil injection products. FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products1.
The available source material provided to readthrough for this item consists only of the announcement's title, repeated across the record. It does not include further detail on the specific labeling language adopted, the rationale behind the change, or any accompanying clinical data.
Because the underlying FDA notice does not elaborate beyond this title in the material supplied, readthrough cannot report additional specifics such as the exact wording added to the label, the date the change takes effect, or any recommendations for clinicians or patients tied to DPD status. Readers seeking the full content of the labeling update should consult the FDA's complete notice directly, as the source document here does not provide further text to cite.
No additional milestones, deadlines, or company-specific details were included in the material reviewed for this story.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.